{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:36:01Z","timestamp":1787160961979,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,27]],"date-time":"2012-01-27T00:00:00Z","timestamp":1327622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,1,27]],"date-time":"2012-01-27T00:00:00Z","timestamp":1327622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The idiopathic inflammatory myopathies are rare diseases for which data regarding the natural history, response to therapies and factors affecting mortality are needed. We performed this study to examine the effects of treatment and clinical features on survival in polymyositis and dermatomyositis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 160 consecutive patients (77 with polymyositis and 83 with dermatomyositis) seen at the University of Michigan from 1997 to 2003 were included. Medical records were abstracted for clinical, laboratory and therapeutic data, including initial steroid regimen and immunosuppressive use. State vital records were utilized to derive mortality and cause of death data. Survival was modeled by left-truncated Kaplan-Meier estimation and Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 5- and 10-year survival estimates were 77% (95% CI = 66 to 85), and 62% (95% CI = 48 to 73), respectively, and the rates were similar for polymyositis and dermatomyositis. Survival between the sexes was similar through 5 years and significantly lower thereafter for males (10-year survival: 18% male, 73% female;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002 for 5- to 10-year interval). The sex disparity was restricted to the polymyositis group. Increased age at diagnosis and non-Caucasian race were associated with lower survival. Intravenous versus oral corticosteroid use was associated with a higher risk of death among Caucasians (HR = 10.6, 95% CI = 2.1 to 52.8). Early survival between patients treated with methotrexate versus azathioprine was similar, but survival at 10 years was higher for the methotrexate-treated group (76% vs 52%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.046 for 5- to 10-year interval).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients treated initially with intravenous corticosteroids had higher mortality, which was likely related to disease severity. Both methotrexate and azathioprine showed similar early survival benefits as first-line immunosuppressive drugs. Survival was higher between 5 and 10 years in the methotrexate-treated group, but could not be confirmed in multivariable modeling for the full follow-up period. Other important predictors of long-term survival included younger age, female sex and Caucasian race.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar3704","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T13:55:37Z","timestamp":1327931737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine"],"prefix":"10.1186","volume":"14","author":[{"given":"Elena","family":"Schiopu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J","family":"Crofford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,27]]},"reference":[{"key":"3467_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet. 2003, 362: 971-982. 10.1016\/S0140-6736(03)14368-1.","journal-title":"Lancet"},{"key":"3467_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.23571","volume":"59","author":"M Fathi","year":"2008","unstructured":"Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, Lundberg IE: Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008, 59: 677-685. 10.1002\/art.23571.","journal-title":"Arthritis Rheum"},{"key":"3467_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson DL, Gange SJ, Rose NR, Graham NM: Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997, 84: 223-243. 10.1006\/clin.1997.4412.","journal-title":"Clin Immunol Immunopathol"},{"key":"3467_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","volume":"33","author":"GS Cooper","year":"2009","unstructured":"Cooper GS, Bynum ML, Somers EC: Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009, 33: 197-207. 10.1016\/j.jaut.2009.09.008.","journal-title":"J Autoimmun"},{"key":"3467_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/art.1780140210","volume":"14","author":"TA Medsger Jr","year":"1971","unstructured":"Medsger TA, Robinson H, Masi AT: Factors affecting survivorship in polymyositis: a life-table study of 124 patients. Arthritis Rheum. 1971, 14: 249-258. 10.1002\/art.1780140210.","journal-title":"Arthritis Rheum"},{"key":"3467_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/0049-0172(86)90014-4","volume":"15","author":"MC Hochberg","year":"1986","unstructured":"Hochberg MC, Feldman D, Stevens MB: Adult onset polymyositis\/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum. 1986, 15: 168-178. 10.1016\/0049-0172(86)90014-4.","journal-title":"Semin Arthritis Rheum"},{"key":"3467_CR7","first-page":"263","volume":"14","author":"YM Maugars","year":"1996","unstructured":"Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM: Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996, 14: 263-274.","journal-title":"Clin Exp Rheumatol"},{"key":"3467_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10067-005-1164-z","volume":"25","author":"A Airio","year":"2006","unstructured":"Airio A, Kautiainen H, Hakala M: Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006, 25: 234-239. 10.1007\/s10067-005-1164-z.","journal-title":"Clin Rheumatol"},{"key":"3467_CR9","first-page":"CD003643","volume":"3","author":"EH Choy","year":"2005","unstructured":"Choy EH, Hoogendijk JE, Lecky B, Winer JB: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2005, 3: CD003643-","journal-title":"Cochrane Database Syst Rev"},{"key":"3467_CR10","unstructured":"World Health Organization: ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification. Geneva: World Health Organization"},{"key":"3467_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975, 292: 344-347. 10.1056\/NEJM197502132920706.","journal-title":"N Engl J Med"},{"key":"3467_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975, 292: 403-407. 10.1056\/NEJM197502202920807.","journal-title":"N Engl J Med"},{"key":"3467_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/rheumatology\/41.1.22","volume":"41","author":"SM Sultan","year":"2002","unstructured":"Sultan SM, Ioannou Y, Moss K, Isenberg DA: Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002, 41: 22-26.","journal-title":"Rheumatology (Oxford)"},{"key":"3467_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/08916930903002453","volume":"42","author":"MJ Kaplan","year":"2009","unstructured":"Kaplan MJ: Endothelial damage and autoimmune diseases. Autoimmunity. 2009, 42: 561-562. 10.1080\/08916930903002453.","journal-title":"Autoimmunity"},{"key":"3467_CR15","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1182\/blood-2003-09-3198","volume":"103","author":"S Rajagopalan","year":"2004","unstructured":"Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan MJ: Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004, 103: 3677-3683. 10.1182\/blood-2003-09-3198.","journal-title":"Blood"},{"key":"3467_CR16","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","volume":"110","author":"MF Denny","year":"2007","unstructured":"Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ: Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007, 110: 2907-2915. 10.1182\/blood-2007-05-089086.","journal-title":"Blood"},{"issue":"5 Suppl 51","key":"3467_CR17","first-page":"S109","volume":"26","author":"IE Lundberg","year":"2008","unstructured":"Lundberg IE, Forbess CJ: Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2008, 26 (5 Suppl 51): S109-S114.","journal-title":"Clin Exp Rheumatol"},{"key":"3467_CR18","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1002\/art.20583","volume":"50","author":"F Buttgereit","year":"2004","unstructured":"Buttgereit F, Straub RH, Wehling M, Burmester GR: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004, 50: 3408-3417. 10.1002\/art.20583.","journal-title":"Arthritis Rheum"},{"key":"3467_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.coph.2010.02.001","volume":"10","author":"CM Spies","year":"2010","unstructured":"Spies CM, Bijlsma JW, Burmester GR, Buttgereit F: Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010, 10: 302-307. 10.1016\/j.coph.2010.02.001.","journal-title":"Curr Opin Pharmacol"},{"key":"3467_CR20","first-page":"545","volume":"43","author":"RK Winkelmann","year":"1968","unstructured":"Winkelmann RK, Mulder DW, Lambert EH, Howard FM, Diessner GR: Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc. 1968, 43: 545-556.","journal-title":"Mayo Clin Proc"},{"key":"3467_CR21","first-page":"207","volume":"4","author":"JR Carpenter","year":"1977","unstructured":"Carpenter JR, Bunch TW, Engel AG, O'Brien PC: Survival in polymyositis: corticosteroids and risk factors. J Rheumatol. 1977, 4: 207-214.","journal-title":"J Rheumatol"},{"key":"3467_CR22","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/art.22205","volume":"54","author":"TP O'Hanlon","year":"2006","unstructured":"O'Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW: HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 2006, 54: 3670-3681. 10.1002\/art.22205.","journal-title":"Arthritis Rheum"},{"key":"3467_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/0003-4819-81-2-182","volume":"81","author":"AL Metzger","year":"1974","unstructured":"Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM: Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974, 81: 182-189.","journal-title":"Ann Intern Med"},{"key":"3467_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG: Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med. 1980, 92: 365-369.","journal-title":"Ann Intern Med"},{"key":"3467_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch TW: Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981, 24: 45-48. 10.1002\/art.1780240107.","journal-title":"Arthritis Rheum"},{"key":"3467_CR26","first-page":"S53","volume":"199","author":"J Miller","year":"2002","unstructured":"Miller J, Walsh Y, Saminaden S, Lecky BRF, Winer JB: Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy [abstract]. J Neurol Sci. 2002, 199: S53-","journal-title":"J Neurol Sci"},{"key":"3467_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL, Fraser D, Targoff IN, Hicks JE, Plotz PH, Miller FW: Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993, 94: 379-387. 10.1016\/0002-9343(93)90148-I.","journal-title":"Am J Med"},{"key":"3467_CR28","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1002\/art.24904","volume":"60","author":"LG Rider","year":"2009","unstructured":"Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW, Adams EM, Ballinger SH, Bowyer SL, Gomez O, Harris-Love MO, Jain MS, Joe GO, Hill S, James-Newton L, Lindsley CB, Passo MH, Perez MD, Plotz PH, Wallace CA, Zemel LS, International Myositis Assessment and Clinical Studies (IMACS) Group: Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009, 60: 3425-3435. 10.1002\/art.24904.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"3467_CR29","first-page":"302","volume":"60","author":"EC Somers","year":"2009","unstructured":"Somers EC, Marder W, Lewis EE, Francis S, Cagnoli PC, DeGuire P, Gordon C, Helmick CG, Leisen JC, Dhar JP, McCune WJ, MILES Group: Michigan Lupus Epidemiology & Surveillance Program (MILES): increased proportion of target-organ threatening involvement among male versus female SLE patients [abstract]. Arthritis Rheum. 2009, 60 (Suppl 10): 302-","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3704\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:27:27Z","timestamp":1728368847000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,2]]}},"alternative-id":["3467"],"URL":"https:\/\/doi.org\/10.1186\/ar3704","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,27]]},"assertion":[{"value":"6 March 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R22"}}